文献速递胸部肿瘤支持与姑息治疗

普那布林对比培非格司亭预防非小细胞肺癌化疗所致中性粒细胞减少的2期随机临床试验

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-11-12

这项在美国、中国、俄罗斯和乌克兰19个中心开展的随机开放标签2期试验,纳入55例铂类化疗后进展的非小细胞肺癌成人患者,比较多西他赛化疗后不同剂量普那布林(5、10、20 mg/m2,第1天)与培非格司亭(6 mg,第2天)预防中性粒细胞减少的效果。主要终点为基于化疗第1周期严重中性粒细胞减少天数确定普那布林3期推荐剂量。普那布林每周期单次给药具有与培非格司亭相似的中性粒细胞保护获益。

要点

  • 普那布林20 mg/m2每周期单次给药与培非格司亭6 mg在严重中性粒细胞减少天数上无显著差异。
  • 随着普那布林剂量递增,任何级别中性粒细胞减少的发生率下降。
  • 试验未检测到安全信号,支持进一步开展3期非劣效性比较。

核心结论

  • 每周期单次给药的普那布林具有与培非格司亭相似的中性粒细胞保护获益。

研究设计与样本

  • 随机、开放标签、4治疗臂的2期临床试验,在美国、中国、俄罗斯和乌克兰的19个癌症治疗中心开展。
  • 纳入55例铂类化疗后进展的非小细胞肺癌成人患者,随机分配至普那布林5、10或20 mg/m2(第1天)或培非格司亭6 mg(第2天)。
  • 所有患者接受多西他赛75 mg/m2(第1天),每21天为一周期,共4个化疗周期。
  • 主要终点为基于化疗第1周期严重中性粒细胞减少天数确定普那布林3期推荐剂量。

主要发现

  • 随着普那布林剂量递增,任何级别中性粒细胞减少的发生率下降。
  • 未检测到安全信号。

关键数值与推荐

  • 普那布林40 mg固定剂量在药理学上等效于20 mg/m2,将在3期试验中与培非格司亭6 mg比较。
  • 3期试验主要终点为严重中性粒细胞减少天数非劣效,次要终点包括骨痛减轻、血小板减少减轻和生活质量维持。

临床怎么用

  • 普那布林可作为非小细胞肺癌患者多西他赛化疗后预防中性粒细胞减少的潜在非GCSF选择。
  • 普那布林每周期单次给药(第1天)可能提供与培非格司亭(第2天)相似的严重中性粒细胞减少保护。
  • 普那布林40 mg固定剂量被选为后续3期试验的推荐剂量。

局限性

  • 本研究为2期、开放标签、样本量较小(55例)的试验,结果需3期试验验证。
  • 主要终点为确定3期推荐剂量而非直接比较疗效,组间比较的统计学效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Plinabulin is a novel, non-granulocyte colony-stimulating factor (GCSF) small molecule with both anticancer and neutropenia-prevention effects. OBJECTIVE: To assess the efficacy and safety of plinabulin compared with pegfilgrastim for the prevention of chemotherapy-induced neutropenia following docetaxel chemotherapy in patients with non-small lung cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, open-label, phase 2 clinical trial of 4 treatment arms that was conducted in 19 cancer treatment centers in the United States, China, Russia, and Ukraine. Participants were adult patients with non-small cell lung cancer whose cancer had progressed after platinum-based chemotherapy. Data were collected from April 2017 through March 2018 and analyzed from August 2019 through February 2020. INTERVENTIONS: All patients received docetaxel 75 mg/m2 on day 1 and were randomly assigned to 1 of 3 doses of plinabulin (5, 10, or 20 mg/m2) on day 1 or to pegfilgrastim 6 mg on day 2. Patients were treated every 21 days for 4 chemotherapy cycles. MAIN OUTCOMES AND MEASURES: The primary end point was the determination of the recommended phase 3 dose of plinabulin based on the days of severe neutropenia during chemotherapy cycle 1. Daily complete blood cell counts and absolute neutrophil counts were drawn during times of anticipated neutropenia during cycle 1. RESULTS: Of the 55 patients randomized and evaluated, the mean (SD) age was 61.3 (10.2) years, and 38 (69.1%) were men. With each escalation of the plinabulin dose, the incidence of any grade of neutropenia decreased. There were no significant differences in mean (SD) days of severe neutropenia among those treated with pegfilgrastim (0.15 [0.38] days) when dosed at day 2 vs plinabulin 20 mg/m2 (0.36 [0.93] days; P = .76) when dosed at day 1, and no safety signals were detected. CONCLUSIONS AND RELEVANCE: Single dose-per-cycle plinabulin has a similar neutropenia protection benefit as pegfilgrastim. Plinabulin 40 mg fixed dose, which is pharmacologically equivalent to 20 mg/m2, will be compared with pegfilgrastim 6 mg in the phase 3 portion of this trial. Noninferior days of severe neutropenia will be the primary end point, and bone pain reduction, thrombocytopenia reduction, and quality of life maintenance will be secondary end points. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03102606.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Blayney DW, Zhang Q, Feng J, et al. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32970104. doi:10.1001/jamaoncol.2020.4429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。